TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Japanese BAY88-8223 Monotherapy Phase II Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Have received docetaxel or not eligible for the first course of docetaxel, i.e. patients who are not fit enough and willing.~* Histologically or cytologically confirmed adenocarcinoma of the prostate~* Multiple bone metastases~* Either regular (not occasional) analgesic medication use for cancer-related bone pain or treatment with external beam radiotherapy (EBRT) for bone pain.~* Best standard of care(BSoC) is regarded as the routine standard of care.~Exclusion Criteria :~* Treatment with cytotoxic chemotherapy within previous 4 weeks, or planned during the treatment period~* History of visceral metastasis, or presence of visceral metastasis

- Gender: MALE
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Radium-223 dichloride (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Aspirin Desensitization Registry in Patients With Aspirin Hypersensitivity

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* history of aspirin hypersensitivity~* acute coronary syndrome or known/suspected stable coronary artery disease~* intent to undergo percutaneous coronary intervention~Exclusion Criteria:~* withdrawal of consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study of Trabectedin for the Treatment of Localized Myxoid / Round Cell Liposarcoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Pathological diagnosis of myxoid / round cell liposarcoma (MRCL) and availability of pathology specimens for central review and pharmacogenomic studies~* Clinical evidence of locally advanced (Stage III), non-metastatic tumor, including locally recurring disease after initial surgery~* Measurable disease (by Response Evaluation Criteria In Solid Tumors \[RECIST\])~* No prior chemotherapy or radiation (except for adjuvant post-operative radiotherapy)~* Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0-2~Exclusion Criteria:~* Known hypersensitivity to any of the components of the trabectedin intravenous (iv) formulation or dexamethasone~* Pregnant or lactating women and women of reproductive potential who are not using effective contraceptive methods~* History of another neoplastic disease (except basal cell carcinoma or cervical carcinoma in situ adequately treated) unless in remission for 5 years or longer~* Known distant metastases~* Other serious illnesses such as congestive heart failure or angina pectoris, myocardial infarction within 1 year before enrollment, uncontrolled arterial hypertension or arrhythmias

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Trabectedin (Type: EXPERIMENTAL): Trabectedin at a dose of 1.5 milligram per meter square (mg/m\^2) will be given as an intravenous (iv) infusion (a fluid or a medicine delivered into a vein by way of a needle) over 24-hour every 3 weeks for a minimum of 3 and a maximum of 6 cycles prior to definitive surgery. Dexamethasone 20 mg iv will also be administered within 30 minutes before start of each trabectedin infusion.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Treatment Effect of QBECO in Moderate to Severe Crohn's Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* An adult, age 18 and above~* Diagnosed with Crohn's disease AT LEAST six (6) months prior to screening~* Crohn's disease diagnosis was verified by one of these procedures: 1) Colonoscopy 2) Capsule endoscopy 3) Computed Tomography (CT) scan 4) Magnetic Resonance Imaging (MRI) 5) Ultrasound~* Active Crohn's disease at the time of screening~* Female participants: Agree to practice two effective methods of contraception, at the same time, from the time of signing the informed consent form, during the entire study treatment and for two (2) months after taking the last dose of study treatment.~* Male participants: Agree to practice effective barrier contraception during the entire study treatment period and for two (2) months after taking the last dose of study treatment.~Exclusion Criteria:~* Currently pregnant or breastfeeding~* Have known or suspected hypersensitivity to any component of the product~* Had more than three (3) small bowel resections or diagnosis of short bowel syndrome~* Currently anticipate undergoing any major surgical intervention for Crohn's disease during the next six (6) months~* Previously been treated with any Qu Biologics' Site Specific Immunomodulators (SSIs) for any disease~* Diagnosed with chronic (i.e., long term) hepatitis B or C infection~* Diagnosed with congenital (i.e., existing at or before birth) or acquired immunodeficiency (i.e., lack of body defense system). For example, human immunodeficiency virus (HIV) infection, organ transplantation (i.e., specifically received an organ from a donor), etc.~* Daily use of narcotic drugs containing opiates (such as morphine, codeine, etc.) for pain control~* Have a current or recent history (within the past 12 months) of alcohol dependence or illicit drug use, with the exception of medicinal marijuana prescribed by a physician~* Have a history of cancer within the last five (5) years. Exceptions may apply for cervical cancer and some forms of skin cancer

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- QBECO (Type: EXPERIMENTAL): Individualized maintenance dose ranging from 0.01 - 0.2 mL, administered subcutaneously, every other day for a maximum of 16 weeks
- Placebo (Type: PLACEBO_COMPARATOR): Individualized maintenance dose ranging from 0.01 - 0.2 mL, administered subcutaneously, every other day for a maximum of 16 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Long-Term Safety Study of JZP-110 in the Treatment of Excessive Sleepiness in Subjects With Narcolepsy or OSA

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Major Inclusion Criteria:~1. Subject meets one of the following:~   1. Completed Study 14-002 or 14-003 (Group A)~  2. Completed Study 14-004, 15-004, 15-005, ADX-N05 201 or ADX-N05 202 (Group B)~2. Body mass index from 18 to \<45 kg/m2~3. Consent to use a medically acceptable method of contraception~4. Willing and able to provide written informed consent~Major Exclusion Criteria:~1. Female subjects who are pregnant, nursing, or lactating~2. Any other clinically relevant medical, behavioral, or psychiatric disorder other than narcolepsy or OSA that is associated with excessive sleepiness~3. History or presence of bipolar disorder, bipolar related disorders, schizophrenia, schizophrenia spectrum disorders, or other psychotic disorders according to DSM-5 criteria~4. Presence of any acutely unstable medical condition, behavioral or psychiatric disorder (including active suicidal ideation), or surgical history that could affect the safety of the subject or interfere with study efficacy or safety assessments, or the ability of the subject to complete the trial per the judgment of the Investigator~5. History of bariatric surgery within the past year or a history of roux-en-y procedure~6. Presence or history of significant cardiovascular disease~7. Use of any over the counter (OTC) or prescription medications that could affect the evaluation of excessive sleepiness~8. Received an investigational drug other than JZP-110 in the past 30 days or five half-lives (whichever is longer)~9. History of phenylketonuria (PKU) or history of hypersensitivity to phenylalanine-derived products

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- 75 mg - 300 mg of JZP-110 (Type: OTHER): Once Daily Dosing

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Quality Of Life Assessment In Alzheimer's Disease (AD) Patients Receiving Aricept Tablets

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of Alzheimer's Disease~Exclusion Criteria:~* There are no exclusion criteria

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- AD patients (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study Evaluating The Safety And Efficacy Of Desvenlafaxine Succinate For Vasomotor Symptoms In Menopausal Women

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Generally healthy, postmenopausal women who seek treatment for hot flushes~* Body Mass Index (BMI) less than or equal to 34 kg/m\^2~Exclusion Criteria:~* Hypersensitivity to Venlafaxine~* Myocardial infarction an/or unstable angina within 6 months of screening~* History of seizure disorder

- Gender: FEMALE
- Minimum Age: 45 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- 1 (Type: EXPERIMENTAL): desvenlafaxine succinate (DVS) SR
- 2 (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* adult patients \>=18 years of age;~* chronic renal anemia;~* on dialysis therapy for at least 12 weeks before screening;~* receiving IV epoetin for at least 8 weeks before screening.~Exclusion Criteria:~* women who are pregnant, breastfeeding or using unreliable birth control methods;~* administration of another investigational drug within 4 weeks before screening, or during the study period.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- RO0503821 (1x/2 Weeks) (Type: EXPERIMENTAL): Participants received RO0503821 (Mircera \[methoxy polyethylene glycol-epoetin beta\]) once every two weeks intravenously for 52 weeks. Participants received a starting dose of RO0503821 (60, 100, or 180 microgram \[mcg\]) that was based on the Epoetin dose (\<8000, 8000-16000, \>16000 International units \[IU\]/Week) administered during the week preceding the switch to the study drug.
- RO0503821 (1x/4 Weeks) (Type: EXPERIMENTAL): Participants received RO0503821 once every four weeks intravenously for 52 weeks. Participants received a starting dose of RO0503821 (120, 200, or 360 mcg) that was based on the Epoetin dose (\<8000, 8000-16000, \>16000 IU/Week) administered during the week preceding the switch to the study drug.
- Epoetin (1-3x/Weeks) (Type: ACTIVE_COMPARATOR): Participants received their ongoing weekly intravenous dose of Epoetin alfa or beta one, two or three times weekly for 52 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Somatosensory Profiling in Radicular Pain Patients And it's Correlation With Treatment Outcome

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* diagnosis of lower extremity radicular pain regardless of specific or suspected etiologies~* scheduling an epidural steroid injection (ESI)~Exclusion Criteria:~* a major psychiatric disorder requiring a recent (within one month) hospitalization, such as major depression, bipolar disorder, schizophrenia, anxiety disorder, and psychosis~* subject is taking illicit or recreational drug detected through a urine toxicology screen~* subject has had an interventional pain management procedures within the last eight weeks that may alter QST responses including neuraxial or local anesthetic block~* subject had a change in dosage of neuromodulatory pain medication (including gabapentin, pregabalin, cymbalta, amitriptyline, nortriptyline, trileptal, etc) in the past two weeks~* subject is pregnant~* subject has pending litigation involving the current pain condition being treated and studied.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- >30% Pain Relief (Type: OTHER): All subjects have radicular pain and are scheduled to receive an epidural steroid injection (ESI) as a treatment. The ESI treatment is conducted by the subject's clinical physician and is not given as part of the research study procedures. Quantitative Sensory Testing (QST) will be conducted before and after the ESI treatment. QST consists of hot and cold temperature testing using the QST device. This group of subjects received greater than 30% pain relief.
- <30% Pain Relief (Type: OTHER): All subjects have radicular pain and are scheduled to receive an epidural steroid injection (ESI) as a treatment. The ESI treatment is conducted by the subject's clinical physician and is not given as part of the research study procedures. Quantitative Sensory Testing (QST) will be conducted before and after the ESI treatment. QST consists of hot and cold temperature testing using the QST device. This group of subjects received less than 30% pain relief.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Venous Thromboembolic Event (VTE) Prophylaxis in Medically Ill Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female patients aged 40 years or more~* Patients at risk of venous thromboembolic events being hospitalized for acute medical conditions as follows:~  * Heart failure, New York Heart Association (NYHA) class III or IV~ * Active cancer~ * Acute ischemic stroke~ * Acute infectious and inflammatory diseases, including acute rheumatic diseases~ * Acute respiratory insufficiency~ * Additional risk factor for VTE, including reduced mobility~Exclusion Criteria:~* Conditions that contraindicate the use of antithrombotic therapy with the Low Molecular-Weight Heparin (LMWH) enoxaparin~* Conditions that may increase the risk of bleeding, including intracranial hemorrhage~* Required drugs or procedures which may interfere with the study treatment~* Concomitant conditions or diseases which may increase the risk of study subjects or interfere with the study outcome~* General conditions in which subjects are not suitable to participate in the study

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Rivaroxaban (Xarelto, BAY59-7939) (Type: EXPERIMENTAL): Participants received 10 mg oral rivaroxaban tablet once daily (OD) for 35 +/- 4 days, plus subcutaneous enoxaparin-matched placebo solution OD for 10 +/- 4 days
- Enoxaparin (Type: ACTIVE_COMPARATOR): Participants received oral rivaroxaban-matched placebo tablet OD for 35 +/- 4 days, plus 40 mg subcutaneous enoxaparin solution OD for 10 +/- 4 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Safety of Two Influenza Vaccines in Children and Adolescents 3 to <18 Years of Age at Risk for Influenza-Related Complications

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Individuals 3 to \<18 years of age with underlying medical conditions that indicate an increased risk of complications from influenza infection.~* Further eligibility criteria may be discussed by contacting the site(s)~Exclusion Criteria:~* Individuals with any fatal prognosis of an underlying medical condition (\<12 month life expectancy).~* Individuals hospitalized at the time of enrolment.~* Individuals with a history of any anaphylaxis, serious vaccine reactions, or hypersensitivity to any of the vaccine components.~* Further eligibility criteria may be discussed by contacting the site(s)

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 17 Years
- Healthy Volunteers: t

Study Arms:
- TIVc (Type: EXPERIMENTAL): flu vaccine
- TIV (Type: ACTIVE_COMPARATOR): flu vaccine

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Efficacy and Safety of Secukinumab in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Subjects must give a written, signed and dated informed consent.~2. Men or women at least 18 years of age at time of screening.~3. Chronic plaque-type psoriasis present for at least 6 months and diagnosed before Baseline.~4. Moderate to severe psoriasis as defined at Baseline by:~   * PASI score of 12 or greater, and~  * IGA mod 2011 score of 3 or greater (based on a static scale of 0 - 4), and~  * Body Surface Area (BSA) affected by plaque-type psoriasis of 10% or greater.~5. Candidate for systemic therapy. This is defined as a subject having moderate to severe chronic plaque-type psoriasis that is inadequately controlled by~   * topical treatment and/or,~  * phototherapy and/or,~  * previous systemic therapy.~Exclusion Criteria:~1. Forms of psoriasis other than chronic plaque-type (e.g., pustular, erythrodermic and guttate psoriasis) at Screening or Baseline.~2. Drug-induced psoriasis.~3. Ongoing use of prohibited treatments.~4. Previous exposure to secukinumab (AIN457) or any other biologic drug directly targeting IL-17 or the IL-17 receptor.~5. Use of other investigational drugs at the time of enrollment, or within 5 half-lives of enrollment, or within 30 days until the expected pharmacodynamic effect has returned to baseline, whichever is longer; or longer if required by local regulations.~6. Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Secukinumab 150mg (Type: EXPERIMENTAL): Secukinumab 150mg s.c.
- Secukinumab 300mg (Type: EXPERIMENTAL): Secukinumab 300mg s.c.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo to secukinumab s.c

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparative Efficacy of an Intensified Re-vaccination Scheme for Hepatitis B Virus Infection Among Patients Infected With HIV .

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Older than 18 years of age.~* Patients infected with Human Immunodeficiency Virus (HIV)~* Failed previous vaccination with a standard dose scheme of recombinant hepatitis B vaccine (20mcg at 0, 1 and 6 months). Nonresponders will be considered as those patients presenting a hepatitis B surface antigen antibody titer lower than 10UI/mL 4 to 8 weeks after the last dose of the vaccine.~* Provision of informed consent.~Exclusion Criteria:~* Proven Hepatitis B virus infection (acute or chronic).~* Proven hypersensitivity to the vaccine or any of its components.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Recombinant Hepatitis B Virus Vaccine (High Dose) (Type: EXPERIMENTAL): Patients allocated to this arm will receive three doses of 40mcg each of recombinant hepatitis B vaccine (Engerix-B (R)). Doses will be administered at 0, 1 and 2 months.
- Recombinant Hepatitis B Virus Vaccine (Standard Dose) (Type: ACTIVE_COMPARATOR): Patients allocated to this arm will receive three doses of 20mcg each of recombinant hepatitis B vaccine (Engerix-B (R)). Doses will be administered at 0, 1 and 2 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete